Resverlogix cannot afford to fail the COVID trial. It will make it that much harder to fund BOM2 unless of course, that's hopefully in the bag already in collaborating with the Supreme Council of the Arab-African Economy. IPEX may have failed presumably the Company's Phase 2 clinical trial first primary endpoint, Resverlogix has failed to meet primary endpoints twice already. Do or die? ... dunno!

Betting success ... Koo